Estándar de tratamiento en primera línea de cáncer de páncreas metastásico: ¿ABRAXANE-GEMCITABINA o FOLFIRINOX? - page 13

Giordano et al. J Clin Oncol 33, 2015 (suppl 3; abstr 424)

Overall survival

ASCO-GI 2015: Giordano et al.

Median OS 11 m

Median PFS 7 m

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,3,4,5,6,7,8,9,10,11,12 14,15,16,17,18,19,20,21,22